Rilematovir
- Generic Name
- Rilematovir
- Drug Type
- Small Molecule
- Chemical Formula
- C21H20ClF3N4O3S
- CAS Number
- 1383450-81-4
- Unique Ingredient Identifier
- NQ99E8OH3P
- Background
Rilematovir is under investigation in clinical trial NCT04056611 (Effects of JNJ-53718678 in Adult and Adolescent Participants Who Had a Hematopoietic Stem Cell Transplantation and Who Are Infected With Respiratory Syncytial Virus (RSV)).
A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Multiple Doses of Orally Administered JNJ-53718678 in Infants Hospitalized With Respiratory Syncytial Virus (RSV) Infection
Phase 1
Terminated
- Conditions
- Virus DiseasesRespiratory Syncytial Virus Infections
- Interventions
- Drug: Placebo
- First Posted Date
- 2015-11-01
- Last Posted Date
- 2019-12-06
- Lead Sponsor
- Janssen Sciences Ireland UC
- Target Recruit Count
- 45
- Registration Number
- NCT02593851
A Study to Investigate Safety, Tolerability, and Pharmacokinetics of JNJ 53718678 in Healthy Japanese Adult Participants
- First Posted Date
- 2015-03-25
- Last Posted Date
- 2017-07-11
- Lead Sponsor
- Janssen Sciences Ireland UC
- Target Recruit Count
- 24
- Registration Number
- NCT02398591
Study to Evaluate Antiviral Activity, Safety, and Pharmacokinetics of Repeated Doses of Orally Administered JNJ 53718678 Against Respiratory Syncytial Virus Infection.
Phase 2
Completed
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- Drug: Placebo
- First Posted Date
- 2015-03-13
- Last Posted Date
- 2022-10-26
- Lead Sponsor
- Janssen Sciences Ireland UC
- Target Recruit Count
- 66
- Registration Number
- NCT02387606
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath